Gribero

Active Ingredient:: Dabigatran Etexilate Mesilate
Origin:: EU

Gribero (Dabigatran Etexilate Mesilate)

Q: What is the mechanism of action of Gribero (dabigatran etexilate)?

Gribero directly and reversibly inhibits thrombin (factor IIa), preventing the conversion of fibrinogen to fibrin and thereby reducing clot formation.

Q: For which patients is Gribero approved to prevent stroke?

Gribero is approved for patients with non‑valvular atrial fibrillation who require anticoagulation to lower the risk of stroke and systemic embolism.

Q: Can Gribero be used to treat an existing deep vein thrombosis?

Yes, Gribero is indicated for the treatment of acute deep vein thrombosis and for secondary prevention of recurrent DVT.

Q: Is Gribero suitable for patients with kidney problems?

Gribero should be used with caution in patients with moderate renal impairment and is generally avoided in severe renal impairment (creatinine clearance <30 mL/min).

Q: What are the most common side effects reported with Gribero?

Common side effects include dyspepsia, minor gastrointestinal bleeding, nosebleeds, and easy bruising or small skin hematomas.

Q: What serious adverse events require immediate medical attention while taking Gribero?

Serious events include major bleeding such as intracranial hemorrhage, severe gastrointestinal bleeding, allergic reactions like rash or anaphylaxis, and signs of liver injury.

Q: Should I stop Gribero before surgery?

Patients are generally advised to discontinue Gribero before elective surgical or invasive procedures, following the timing recommendations of their healthcare provider.

Q: Which medications should be avoided while taking Gribero?

Strong P‑gp inhibitors (e.g., ketoconazole, ritonavir), high‑dose NSAIDs or aspirin, and other oral anticoagulants should be avoided due to increased bleeding risk.

Q: Can Gribero be taken with antiplatelet drugs like clopidogrel?

Co‑administration can increase bleeding risk, so it should be used with caution and only under close medical supervision.

Q: Is Gribero safe to use during pregnancy or breastfeeding?

Safety data for Gribero in pregnancy and lactation are limited; it should be prescribed only if the potential benefit justifies the potential risk to the fetus or infant.

Gribero is an oral anticoagulant medication whose active ingredient is dabigatran etexilate mesylate. It is supplied in tablet form (strength not specified) and is marketed in the European Union as a prescription (Rx) product. Gribero belongs to the direct thrombin inhibitor class and works by reversibly blocking thrombin (factor IIa), thereby reducing the formation of fibrin clots. It is intended for use to manage conditions associated with blood clot risk.

Manufacturer / TM Owner

Sandoz Pharmaceuticals D.D.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Gribero is indicated for several thrombo‑embolic conditions where anticoagulation is required.

Prevention of stroke and systemic embolism in patients with non‑valvular atrial fibrillation.
Treatment of acute deep vein thrombosis (DVT) and reduction of recurrence risk.
Initial treatment of pulmonary embolism (PE) and prevention of recurrent PE.
Long‑term secondary prevention of DVT and PE after initial therapy.
Use in patients for whom vitamin K antagonists are unsuitable.

Side Effects

The safety profile of Gribero includes both common and less frequent serious adverse events that may occur during therapy.

Common

Dyspepsia or stomach discomfort.
Minor gastrointestinal bleeding such as occult blood in stool.
Nosebleeds (epistaxis).
Easy bruising or small skin hematomas.

Serious

Major bleeding events, including intracranial hemorrhage.
Gastrointestinal perforation or severe ulceration.
Allergic reactions such as rash, angioedema, or anaphylaxis.
Elevated liver enzymes indicating hepatic injury.

Precautions & Warnings

Before initiating Gribero, clinicians should assess patient-specific factors and monitor for conditions that increase bleeding risk.

History of active or recent major bleeding.
Severe renal impairment (creatinine clearance <30 mL/min).
Uncontrolled hypertension.
Concomitant use of other anticoagulants or antiplatelet agents.
Pregnancy or breastfeeding status, as safety data are limited.
Planned surgical or invasive procedures requiring temporary discontinuation.

Avoid Interactions

Gribero can interact with several medicines, affecting its anticoagulant effect or increasing bleeding risk.

Avoid

Strong P‑glycoprotein (P‑gp) inhibitors such as ketoconazole, itraconazole, or ritonavir.
Non‑steroidal anti‑inflammatory drugs (NSAIDs) and aspirin at high doses.
Other oral anticoagulants (e.g., warfarin, apixaban, rivaroxaban).

Use with caution

Moderate P‑gp inhibitors (e.g., amiodarone, quinidine, verapamil).
Antiplatelet agents like clopidogrel or ticagrelor.
Certain antifungal agents (e.g., fluconazole) and antibiotics (e.g., erythromycin).

Frequently Asked Questions

Gribero directly and reversibly inhibits thrombin (factor IIa), preventing the conversion of fibrinogen to fibrin and thereby reducing clot formation.

Gribero is approved for patients with non‑valvular atrial fibrillation who require anticoagulation to lower the risk of stroke and systemic embolism.

Yes, Gribero is indicated for the treatment of acute deep vein thrombosis and for secondary prevention of recurrent DVT.

Gribero should be used with caution in patients with moderate renal impairment and is generally avoided in severe renal impairment (creatinine clearance <30 mL/min).

Common side effects include dyspepsia, minor gastrointestinal bleeding, nosebleeds, and easy bruising or small skin hematomas.

Serious events include major bleeding such as intracranial hemorrhage, severe gastrointestinal bleeding, allergic reactions like rash or anaphylaxis, and signs of liver injury.

Patients are generally advised to discontinue Gribero before elective surgical or invasive procedures, following the timing recommendations of their healthcare provider.

Strong P‑gp inhibitors (e.g., ketoconazole, ritonavir), high‑dose NSAIDs or aspirin, and other oral anticoagulants should be avoided due to increased bleeding risk.

Co‑administration can increase bleeding risk, so it should be used with caution and only under close medical supervision.

Safety data for Gribero in pregnancy and lactation are limited; it should be prescribed only if the potential benefit justifies the potential risk to the fetus or infant.

Gribero is supplied as oral tablets taken with or without food, according to the prescribing information and the dose recommended by a healthcare professional.

Routine laboratory monitoring of coagulation is generally not required, but renal function, liver enzymes, and signs of bleeding should be periodically assessed.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 07 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.